Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q3 FY25 Earnings Presentation
35 slides from Gufic Biosciences's earnings presentation, Feb 14, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
41/LG/SE/FEB/2025/GBSL February 14, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Present
Slide 2: Delivering Care & Cure - Investor Presentation February 2025
Delivering Care & Cure Investor Presentation February 2025
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Lim ited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This presentation does not constitute or form part of any offer or invitation
Slide 4: Q3 FY25 Business & Financial Highlights
Q3 FY25 Business & Financial Highlights
Slide 5: Q3 FY25 Business Highlights: Indore Capex Update, Criticare Division
Q3 FY25 Business Highlights Indore Capex Update Post completion of all the validation activities, Indore has commenced production Gradual scale up in coming quarters as products and various commercial batch sizes are rolled up post completion of audits by customers and regulatory bodies. Critica
Slide 6: Q3 FY25 Business Highlights: Criticare pipeline
Q3 FY25 Business Highlights Criticare’s pipeline of products that address key therapeutic gaps and are complex to manufacture Domestic Business Breakup Drug Class Unique Advantages Complexity in Manufacturing Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual
Slide 7: Ferticare Division – Assisted Reproductive Technology
Q3 FY25 Business Highlights Ferticare Division – Advancing Science-Driven Solutions in Assisted Reproductive Technology (ART) The Ferticare Division is committed to not only addressing standard ART protocols but also offering targeted solutions for challenging patient groups, such as poor responders
Slide 8: Aesthaderm Published Comparative Study in JCAS
Q3 FY25 Business Highlights Aesthaderm Published Comparative Study in renowned Journal JCAS Statistical signifcance reduction in crow’s feet wrinkles by STUNNOX® was observed & found non-inferior to international innovator brand with no adverse events. 7
Slide 9: Aesthaderm & Nurocare Division
Q3 FY25 Business Highlights Aesthaderm & Nurocare Division – Building a Strong Foundation for Growth in Aesthetic Dermatology & Neurology Focus on Building Injector Base Conducted comprehensive training workshops for doctors, focusing on both basic and advanced injection techniques for Stunnox and
Slide 10: Stellar & Spark Division – Expanding Specialty Therapies
Q3 FY25 Business Highlights Stellar & Spark Division – Expanding Specialty Therapies The Stellar Division continues to strengthen its presence across orthopedics, gastroenterology, reproductive health, and women's wellness by introducing scientifically driven and patient-centric solutions. Vonobas
Slide 11: Healthcare Division – Pain Management & Ayurveda-Based Therapeutics
Q3 FY25 Business Highlights Healthcare Division – Advancing Pain Management & Ayurveda-Based Therapeutics The Healthcare Division continues to strengthen its presence in musculoskeletal health and Ayurveda-driven pain management, offering scientifically validated, integrative treatment solutions. •
Slide 12: Sparsh Division – Strengthening Market Position
Q3 FY25 Business Highlights Sparsh Division – Strengthening Market Position Strategic Product Expansion: Sparsh has added select contrast media to its portfolio, positioning itself uniquely in the market as one of the few companies offering these essential products for diagnostic imaging. Unique
Slide 13: International Business
Q3 FY25 Business Highlights International Business Gufic Biosciences has strategically focused on expanding its footprint in regulated and semi-regulated international markets. This focus is driven by a commitment to high-quality, affordable medicines combined with a robust regulatory compliance str
Slide 14: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical • Positive Results from Mouse Studies: API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader • Selvax conducted comprehensive studies in mice us
Slide 15: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 16: Profit & Loss Statement
Profit & Loss Statement Particulars (in Rs. Crore) Q3 FY25 Q2 FY25 Q3 FY24 9M FY25 9M FY24 FY24 FY23 Total Revenue 207.8 204.2 201.8 614.8 616.7 806.7 690.6 EBITDA 35.8 38.7 36.9 111.6 112.9 148.05 137.2 EBITDA Margin % 17.23% 18.95% 18.29% 18.15% 18.31% 18.35% 19.87% Profit before Tax 26.3 29.3 29.
Slide 17: Company Overview
Company Overview
Slide 18: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 19: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Natural Products (Topical/Liquid) Amphoter
Slide 20: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Plant Readiness: The Indore facility is fully operational Facility Carbapenems (Lyophilized / Dry and ready for production, with all n
Slide 21: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 22: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s 200+ Field Force: 250 Therapy Areas: Antibacterial, Field Force: >150 Therapy Areas: Hormones, Field Force: >180 Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 23: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 24: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 25: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 26: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 27: Extensive Sales, Distribution and IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure 23 Carrying & Forwarding Retail coverage of more than (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 28: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 29: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 30: Historical Financials
Historical Financials
Slide 31: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Total Revenue 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 148.0 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 18.3% 19.8% 19.3% 17.8% 15.1% 15.8% Profit before Tax 115.7 106.7 126.8 57.7 30.1 40.2 PBT Margin % 14.3% 15.4% 16.2% 1
Slide 32: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 9.7 9.7 9.7 9.7 7.8 Other Equity 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 532.5 347.8 269.1 173.4 129.3 75.3 Non-Current Liabilities Financial Liab
Slide 33: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 307.1 169.6 40.9 13.4 30.6 9.6 Right of use assets 14.9 3
Slide 34: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before working capital changes 149.8 136.4
Slide 35: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000